biota pharmaceuticals inc (BOTA) Key Developments
Biota Pharmaceuticals, Inc. Commences Dosing in Vapendavir SPIRITUS Phase 2b Trial
Mar 3 15
Biota Pharmaceuticals, Inc. announced that it has commenced dosing of patients in its Phase 2b SPIRITUS trial of vapendavir. The goal of the study is to enroll approximately 150 laboratory-confirmed human rhinovirus (HRV) infected patients with moderate-to-severe asthma from the United States and multiple European countries over the next 12 months and to report top-line data in mid-2016. The primary endpoint of this multi-center, randomized, double-blind, placebo-controlled dose-ranging study is the change from baseline to study day 14 measured by an asthma control questionnaire (ACQ)-6 total score. The secondary endpoints are focused on safety and tolerability, lung function assessments such as forced expiratory volume in one second, incidence of asthma exacerbations, assessments of the severity and duration of cold symptoms measured by the Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) and virological assessments such as changes in viral load.
Anaconda Pharma SAS, Biota Pharmaceuticals, Inc. - M&A Call
Feb 26 15
To discuss agreement to acquire Anaconda Pharma
Biota Pharmaceuticals, Inc. Presents at 27th Annual ROTH Conference, Mar-10-2015 11:00 AM
Feb 13 15
Biota Pharmaceuticals, Inc. Presents at 27th Annual ROTH Conference, Mar-10-2015 11:00 AM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States. Speakers: Joseph M. Patti, Chief Executive Officer and President.
Biota Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Month Periods Ended December 31, 2014
Feb 5 15
Biota Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter and six month periods ended December 31, 2014. For the quarter, the company reported total revenue of $13.9 million against $18.5 million a year ago. Profit from operations was $6.4 million against loss of $0.1 million a year ago. Profit before tax was $6.5 million against loss before tax of $0.1 million a year ago. Net profit was $6.5 million or $0.19 per diluted share against net loss of $0.1 million or $0.00 per diluted share a year ago. The $6.6 million change in net income from the prior fiscal year period was primarily due to a $9.8 million decrease in the cost of revenue, a $1.4 million increase in foreign exchange gain, a $0.5 million decrease in general and administrative expense and a $0.1 million increase in interest income, offset in part by a $4.6 million decrease in revenue and a $0.6 million increase in research and development expense. Revenue decreased due to a $5.0 million decrease in revenue from services related to the termination of the Company's contract with BARDA on May 7, 2014 and a $0.1 million decrease in other revenue due to a reduced level of grant-related research activities, offset in part by a $0.5 million increase in royalty revenues primarily related to an increase in seasonal sales of Relenza® and Inavir®.
For the six months, the company reported total revenue of $14.6 million against $30.8 million a year ago. Loss from operations was $0.6 million against $4.2 million a year ago. Loss before tax was $0.4 million against $4.1 million a year ago. Net loss was $0.4 million or $0.01 per diluted share against $4.0 million $0.14 per diluted share a year ago.
Biota Pharmaceuticals, Inc. to Report Q2, 2015 Results on Feb 05, 2015
Jan 29 15
Biota Pharmaceuticals, Inc. announced that they will report Q2, 2015 results at 9:00 AM, US Eastern Standard Time on Feb 05, 2015